Massimo Fiandaca
Columbia, MDNPI 1326063264
Payments from drug & device makers
What this record shows
This record is dominated by other: $577,303 of the $577,303 with a category attached, or 100.0%. Asklepios Biopharmaceutical Inc. accounts for 88.0% of it on its own, with 1 other manufacturer making up the rest.
$577,303in general payments, 2019–2025
Across 3 payments — averaging $192,434 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Asklepios Biopharmaceutical Inc.$508K
- Bayer$69K
What the payments were for
- Other$577,303100%
General payments by program year
22
23
24
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Asklepios Biopharmaceutical Inc. | 2 | $508,022 |
| Bayer | 1 | $69,281 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.